Advancements in Lymphoma Treatment

This chapter explores the efficacy of CAR T-cell therapy, bispecific agents, and bendamustine in treating lymphoma, particularly relapsed refractory follicular and mantle cell lymphoma. It highlights clinical trial data on response rates, durability of treatment outcomes, and the importance of achieving complete responses. The discussion also emphasizes patient management considerations, toxicity profiles, and the potential of emerging therapies like odronexumab.